GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rocket Pharmaceuticals Inc (NAS:RCKT) » Definitions » Other Current Assets

Rocket Pharmaceuticals (Rocket Pharmaceuticals) Other Current Assets : $5.05 Mil (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Rocket Pharmaceuticals Other Current Assets?

Rocket Pharmaceuticals's other current assets for the quarter that ended in Dec. 2023 was $5.05 Mil.

Rocket Pharmaceuticals's quarterly other current assets increased from Jun. 2023 ($5.03 Mil) to Sep. 2023 ($9.69 Mil) but then declined from Sep. 2023 ($9.69 Mil) to Dec. 2023 ($5.05Mil).

Rocket Pharmaceuticals's annual other current assets increased from Dec. 2021 ($3.32 Mil) to Dec. 2022 ($7.67 Mil) declined from Dec. 2022 ($7.67 Mil) to Dec. 2023 ($5.05 Mil).


Rocket Pharmaceuticals Other Current Assets Historical Data

The historical data trend for Rocket Pharmaceuticals's Other Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rocket Pharmaceuticals Other Current Assets Chart

Rocket Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Current Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.64 4.63 3.32 7.67 5.05

Rocket Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Other Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.67 6.95 5.03 9.69 5.05

Rocket Pharmaceuticals Other Current Assets Calculation

Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:


Cash
Trade Receivables
Inventory

The assets grouped under other current assets are most commonly:


Prepaid Expenses
Tax Assets
Non-Trade Receivables
Other (too numerous to list)

Some companies can and do choose to report each of these items separately.

Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.

Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.

Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.

Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.

There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.

At most companies, other current assets are a small and unimportant part of the total balance sheet.


Rocket Pharmaceuticals Other Current Assets Related Terms

Thank you for viewing the detailed overview of Rocket Pharmaceuticals's Other Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Rocket Pharmaceuticals (Rocket Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
9 Cedarbrook Drive, Cranbury, NJ, USA, 08512
Rocket Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis.
Executives
John Militello officer: See Remarks C/O IMMUNE PHARMACEUTICALS INC., 430 EAST 29TH STREET, SUITE 940, NEW YORK NY 10016
Gotham Makker director 430 EAST 29TH STREET, SUITE 1040, NEW YORK NY 10016
Gaurav Shah director, officer: See Remarks 430 EAST 29TH STREET, SUITE 1040, NEW YORK NY 10016
Kinnari Patel officer: Chief Operating Officer 430 EAST 29TH STREET, SUITE 1040, NEW YORK NY 10016
Mark Andrew White officer: Chief Medical Officer C/O ROCKET PHARMACEUTICALS, INC., 9 CEDARBROOK DRIVE, CRANBURY NJ 08512
Jonathan David Schwartz officer: Chief Medical Officer 430 EAST 29TH STREET, SUITE 1040, NEW YORK NY 10016
Rtw Investments, Lp 10 percent owner 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014
Fady Ibraham Malik director 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Martin Wilson officer: General Counsel C/O TELIGENT, INC., 105 LINCOLN AVENUE, BUENA NJ 08310
Carlos Garcia-parada officer: Chief Financial Officer C/O ROCKET PHARMACEUTICALS, INC., 350 FIFTH AVENUE SUITE 7530, NEW YORK NY 10118
Elisabeth Bjork director C/O ROCKET PHARMACEUTICALS, INC., 350 FIFTH AVENUE, SUITE 7530, NEW YORK NY 10116
Kamran Alam officer: SVP - Finance & PFO 350 FIFTH AVENUE, SUITE 7530, NEW YORK NY 10118
David P Southwell director, officer: See Remarks C/O INOTEK PHARMACEUTICALS CORPORATION, 91 HARTWELL AVENUE, LEXINGTON MA 02421
Naveen Yalamanchi director 412 WEST 15TH STREET, 9TH FLOOR, NEW YORK NY 10019
Brian Batchelder officer: See Remarks 430 EAST 29TH STREET, SUITE 1040, NEW YORK NY 10016

Rocket Pharmaceuticals (Rocket Pharmaceuticals) Headlines

From GuruFocus

Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences

By Business Wire Business Wire 04-11-2023

Insider Alert: An Insider Just Sold Rocket Pharmaceuticals Inc Shares

By GuruFocus Research GuruFocus Editor 05-21-2023